Genetesis, the market leader in the design, development and commercialization of biomagnetic imaging solutions, today announced its new Scientific Advisory Board (SAB). The group is comprised of world-class experts, researchers and thought leaders spanning cardiology, emergency medicine and radiology. The newly appointed SAB will play a key role in helping to shape the company’s product and commercial roadmap, clinical strategy and R&D activities.
“We are pleased to announce this Scientific Advisory Board, and to be working closely with some of the scientific and clinical luminaries in our field,” said Peeyush Shrivastava, CEO of Genetesis. “The experts joining this team will be instrumental in achieving our clinical and product development plans for CardioFlux, and we appreciate their support of our mission to create a more patient and provider centric standard of care.”
The members of the Genetesis SAB include (alphabetically listed):